Enzyme found to be a predictive marker of survival in head and neck cancer

New research suggests that levels of ERCC1 -- an enzyme that helps repair cisplatin-related DNA damage -- offer a predictive marker of survival in squamous carcinoma of the head and neck. The findings might eventually help guide treatment selection for patients with recurrent and metastatic disease.

Read the whole article on Science Daily

More from Science Daily